1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- Bayer AG
- Bristol-Myers Squibb Co.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- MORE
The gastrointestinal stromal tumors therapeutics market has witnessed an increase in the use of therapeutics. The demand for therapeutics is expected to increase owing to the increasing advances in the research of targeted checkpoint inhibitors such as programmed cell death protein 1 (PD-1) inhibitors and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors. For instance, the market is expected to benefit significantly from the anticipated launch of KEYTRUDA, a novel PD-1 inhibitor by Merck, during the first half of the forecast period. The drug has shown superior efficacy in the clinical stages for the treatment of gastrointestinal stromal tumors. Also, these drugs are already approved for other indications and have been maintaining a blockbuster status. This would help these drugs to penetrate fast in the global gastrointestinal stromal tumors therapeutics market after their approval and launch, thereby increasing the adoption of therapeutics during the forecast period. Analysts have predicted that the gastrointestinal stromal tumors therapeutics market will register a CAGR of over 6% by 2023.
Market Overview
Increasing awareness campaigns
Gastrointestinal stromal tumors are a rare type of cancer; hence, the awareness of the disease is deficient among the people. As a result, the diagnosis of the indication is often delayed until the late stages due to the lack of knowledge of the symptoms, which is leading to an increase in the challenges with the treatment. Therefore, the morbidity of the disease is high. To overcome this challenge, various organizations are conducting awareness campaigns at both regional level and global level. For instance. The Life Raft Group is a non-profit organization that focuses on providing information, educating medical professionals, and providing support to conduct innovative research for the treatment of gastrointestinal stromal tumors. The organization aims at reducing the time between the first appearance of the symptom to the diagnosis of the disease and between the diagnosis and the treatment. Similarly, the GIST Cancer Research Fund is another organization that is actively involved in increasing the awareness of the indication in the US. Hence, the growth in the number of awareness campaigns is leading to the increasing diagnosis of the disease during the early stages, which is resulting in more patients undergoing treatment on time, thus driving the market growth.
High treatment costs
A significant share of the global gastrointestinal stromal tumor’s therapeutics market is dominated by specialty drugs such as GLEEVEC, STIVARGA, and SUTENT. These drugs are priced very high when compared with traditional chemotherapy drugs due to their ability to target multiple proteins. Most of the patients, who do not have health insurance or access to patient assistance programs by vendors or governments, cannot afford the treatment using these drugs, which reduces the patient adherence and poses a challenge to the market growth. Also, the expected launch of various biologics is likely to increase the costs of treatment during the forecast period. The complex manufacturing process and high R&D costs of biologics often lead to vendors offering these drugs at a high price. These high treatment costs using therapeutics are expected to be one of the significant challenges to market growth during the forecast period.
Competitive Landscape
The market appears to be moderately concentrated. The presence of a few companies, including Bayer AG and Bristol-Myers Squibb Co. makes the competitive environment quite intense. Factors such as the growing geriatric population and the increasing awareness campaigns will provide significant growth opportunities to the gastrointestinal stromal tumors therapeutics companies. Merck & Co. Inc., Novartis AG, and Pfizer Inc. are some of the major companies covered in this report.
Market Overview
Increasing awareness campaigns
Gastrointestinal stromal tumors are a rare type of cancer; hence, the awareness of the disease is deficient among the people. As a result, the diagnosis of the indication is often delayed until the late stages due to the lack of knowledge of the symptoms, which is leading to an increase in the challenges with the treatment. Therefore, the morbidity of the disease is high. To overcome this challenge, various organizations are conducting awareness campaigns at both regional level and global level. For instance. The Life Raft Group is a non-profit organization that focuses on providing information, educating medical professionals, and providing support to conduct innovative research for the treatment of gastrointestinal stromal tumors. The organization aims at reducing the time between the first appearance of the symptom to the diagnosis of the disease and between the diagnosis and the treatment. Similarly, the GIST Cancer Research Fund is another organization that is actively involved in increasing the awareness of the indication in the US. Hence, the growth in the number of awareness campaigns is leading to the increasing diagnosis of the disease during the early stages, which is resulting in more patients undergoing treatment on time, thus driving the market growth.
High treatment costs
A significant share of the global gastrointestinal stromal tumor’s therapeutics market is dominated by specialty drugs such as GLEEVEC, STIVARGA, and SUTENT. These drugs are priced very high when compared with traditional chemotherapy drugs due to their ability to target multiple proteins. Most of the patients, who do not have health insurance or access to patient assistance programs by vendors or governments, cannot afford the treatment using these drugs, which reduces the patient adherence and poses a challenge to the market growth. Also, the expected launch of various biologics is likely to increase the costs of treatment during the forecast period. The complex manufacturing process and high R&D costs of biologics often lead to vendors offering these drugs at a high price. These high treatment costs using therapeutics are expected to be one of the significant challenges to market growth during the forecast period.
Competitive Landscape
The market appears to be moderately concentrated. The presence of a few companies, including Bayer AG and Bristol-Myers Squibb Co. makes the competitive environment quite intense. Factors such as the growing geriatric population and the increasing awareness campaigns will provide significant growth opportunities to the gastrointestinal stromal tumors therapeutics companies. Merck & Co. Inc., Novartis AG, and Pfizer Inc. are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- Bayer AG
- Bristol-Myers Squibb Co.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 07: MARKET SEGMENTATION BY ROA
PART 09: GEOGRAPHIC LANDSCAPE
PART 11: DRIVERS AND CHALLENGES
PART 13: VENDOR LANDSCAPE
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global gastrointestinal stromal tumors therapeutics market pipeline: Overview
Exhibit 18: Global gastrointestinal stromal tumors therapeutics market pipeline: Snapshot
Exhibit 19: RoA - Market share 2018-2023 (%)
Exhibit 20: Comparison by RoA
Exhibit 21: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 23: Parenteral - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Parenteral - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by RoA
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Global rise in geriatric population
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Bayer AG - Vendor overview
Exhibit 51: Bayer AG - Business segments
Exhibit 52: Bayer AG - Organizational developments
Exhibit 53: Bayer AG - Geographic focus
Exhibit 54: Bayer AG - Segment focus
Exhibit 55: Bayer AG - Key offerings
Exhibit 56: Bayer AG - Key customers
Exhibit 57: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 58: Bristol-Myers Squibb Co. - Business segments
Exhibit 59: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 60: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 61: Bristol-Myers Squibb Co. - Key offerings
Exhibit 62: Bristol-Myers Squibb Co. - Key customers
Exhibit 63: Merck & Co. Inc. - Vendor overview
Exhibit 64: Merck & Co. Inc. - Business segments
Exhibit 65: Merck & Co. Inc. - Organizational developments
Exhibit 66: Merck & Co. Inc. - Geographic focus
Exhibit 67: Merck & Co. Inc. - Segment focus
Exhibit 68: Merck & Co. Inc. - Key offerings
Exhibit 69: Merck & Co. Inc. - Key customers
Exhibit 70: Novartis AG - Vendor overview
Exhibit 71: Novartis AG - Business segments
Exhibit 72: Novartis AG - Organizational developments
Exhibit 73: Novartis AG - Geographic focus
Exhibit 74: Novartis AG - Segment focus
Exhibit 75: Novartis AG - Key offerings
Exhibit 76: Novartis AG - Key customers
Exhibit 77: Pfizer Inc. - Vendor overview
Exhibit 78: Pfizer Inc. - Business segments
Exhibit 79: Pfizer Inc. - Organizational developments
Exhibit 80: Pfizer Inc. - Geographic focus
Exhibit 81: Pfizer Inc. - Segment focus
Exhibit 82: Pfizer Inc. - Key offerings
Exhibit 83: Pfizer Inc. - Key customers
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY ROA
- Market segmentation by RoA
- Comparison by RoA
- Oral - Market size and forecast 2018-2023
- Parenteral - Market size and forecast 2018-2023
- Market opportunity by RoA
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bayer AG
- Bristol-Myers Squibb Co.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global gastrointestinal stromal tumors therapeutics market pipeline: Overview
Exhibit 18: Global gastrointestinal stromal tumors therapeutics market pipeline: Snapshot
Exhibit 19: RoA - Market share 2018-2023 (%)
Exhibit 20: Comparison by RoA
Exhibit 21: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 23: Parenteral - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Parenteral - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by RoA
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Global rise in geriatric population
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Bayer AG - Vendor overview
Exhibit 51: Bayer AG - Business segments
Exhibit 52: Bayer AG - Organizational developments
Exhibit 53: Bayer AG - Geographic focus
Exhibit 54: Bayer AG - Segment focus
Exhibit 55: Bayer AG - Key offerings
Exhibit 56: Bayer AG - Key customers
Exhibit 57: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 58: Bristol-Myers Squibb Co. - Business segments
Exhibit 59: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 60: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 61: Bristol-Myers Squibb Co. - Key offerings
Exhibit 62: Bristol-Myers Squibb Co. - Key customers
Exhibit 63: Merck & Co. Inc. - Vendor overview
Exhibit 64: Merck & Co. Inc. - Business segments
Exhibit 65: Merck & Co. Inc. - Organizational developments
Exhibit 66: Merck & Co. Inc. - Geographic focus
Exhibit 67: Merck & Co. Inc. - Segment focus
Exhibit 68: Merck & Co. Inc. - Key offerings
Exhibit 69: Merck & Co. Inc. - Key customers
Exhibit 70: Novartis AG - Vendor overview
Exhibit 71: Novartis AG - Business segments
Exhibit 72: Novartis AG - Organizational developments
Exhibit 73: Novartis AG - Geographic focus
Exhibit 74: Novartis AG - Segment focus
Exhibit 75: Novartis AG - Key offerings
Exhibit 76: Novartis AG - Key customers
Exhibit 77: Pfizer Inc. - Vendor overview
Exhibit 78: Pfizer Inc. - Business segments
Exhibit 79: Pfizer Inc. - Organizational developments
Exhibit 80: Pfizer Inc. - Geographic focus
Exhibit 81: Pfizer Inc. - Segment focus
Exhibit 82: Pfizer Inc. - Key offerings
Exhibit 83: Pfizer Inc. - Key customers
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
FEATURED COMPANIES
- Bayer AG
- Bristol-Myers Squibb Co.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- MORE
The following companies are recognised as the key players in the global gastrointestinal stromal tumor’s therapeutics market: Bayer AG, Bristol-Myers Squibb Co., Merck & Co. Inc., Novartis AG, and Pfizer Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing research funding.”
According to the report, one of the major drivers in this market is the growing adoption of therapeutics.
Further, the report states that one of the major factors hindering the growth of this market is the high treatment costs.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing research funding.”
According to the report, one of the major drivers in this market is the growing adoption of therapeutics.
Further, the report states that one of the major factors hindering the growth of this market is the high treatment costs.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
- Bayer AG
- Bristol-Myers Squibb Co.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
Note: Product cover images may vary from those shown
